Medications for Breast Cancer Earlyonset

6 results

  • aromasin

    (exemestane)
    Pharmacia & Upjohn Company LLC
    AROMASIN is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer after two to three years of tamoxifen, completing a total of five years of therapy. It is also used to treat advanced breast cancer in postmenopausal women progressing after tamoxifen.

  • kadcyla

    (ADO-TRASTUZUMAB EMTANSINE)
    Genentech, Inc.
    KADCYLA® is indicated for treating patients with HER2-positive metastatic breast cancer (MBC) who have received prior trastuzumab and a taxane, or those with early breast cancer (EBC) having residual invasive disease after neoadjuvant therapy. Patient selection is based on an FDA-approved diagnostic.

  • kisqali

    (ribociclib)
    Novartis Pharmaceuticals Corporation
    KISQALI is indicated for the adjuvant treatment of adults with HR-positive, HER2-negative early breast cancer at high risk of recurrence, and for advanced or metastatic HR-positive, HER2-negative breast cancer in combination with aromatase inhibitors or fulvestrant.

  • perjeta

    (Pertuzumab)
    Genentech, Inc.
    PERJETA is indicated for the treatment of HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel, and for early breast cancer in combination with trastuzumab and chemotherapy for neoadjuvant and adjuvant therapies, especially in high-risk patients.

  • phesgo

    (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
    Genentech, Inc.
    PHESGO is indicated for the neoadjuvant and adjuvant treatment of adults with HER2-positive early breast cancer, and for the treatment of adults with HER2-positive metastatic breast cancer in combination with docetaxel, specifically for those who have not received prior anti-HER2 therapy or chemotherapy.

  • verzenio

    (abemaciclib)
    Eli Lilly and Company
    VERZENIO (abemaciclib) is indicated for adults with HR-positive, HER2-negative breast cancer. It is used in combination with endocrine therapy for early breast cancer at high risk of recurrence and for advanced or metastatic cases, either with an aromatase inhibitor, fulvestrant, or as monotherapy after prior treatments.